Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer ...

“It was encouraging to see that cabozantinib resulted in significant delays in disease progression in the CABINET trial—regardless of primary tumor site and grade,” said Jennifer ...

Dublin, March 14, 2025 (GLOBE NEWSWIRE) -- The "Carcinoid Tumor Market" report has been added to ResearchAndMarkets.com's offering. The global demand for advanced carcinoid tumor treatments is ...

The following is a summary of "Controversial Role Of Cd151 In Different Solid Tumors: Promoter Or Suppressor?,” published in ...

Pancreatic cancer is on the rise in the United States, but there's another, less common type called pancreatic neuroendocrine ...

The FDA approval was based on results from the CABINET study, a phase 3 pivotal trial evaluating cabozantinib compared with ...